Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for its content [1] - The quarterly financial report has not been audited [2] - The net profit attributable to shareholders increased by 2.77% year-on-year, while the net profit excluding non-recurring gains and losses grew by 4.69% year-on-year [2] Financial Data - The report period refers to the three months from the beginning to the end of the quarter [2] - The company recognized a total of 13.2962 million yuan in stock incentive expenses from the beginning of the year to the end of the reporting period [2] - The company’s repurchase account held 2,179,346 shares, accounting for 1.23% of the total share capital of 176,532,256 shares as of the end of the reporting period [5] Shareholder Information - There are no changes in the borrowing or returning of shares by the top ten shareholders due to transfer and financing [6] - The report does not include any additional important information regarding the company's operational situation during the reporting period [6]

Core Insights - The company reported a revenue of 364,685,045.87 yuan for the third quarter of 2025, representing a year-on-year decline of 1.55% [1] - The net profit attributable to shareholders of the listed company was 83,590,556.58 yuan, showing a year-on-year increase of 18.52% [1] Financial Performance - Revenue for Q3 2025: 364.69 million yuan, down 1.55% year-on-year [1] - Net profit for Q3 2025: 83.59 million yuan, up 18.52% year-on-year [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) reported a slight decline in revenue for the first three quarters of 2025, while net profit showed a modest increase, indicating a mixed performance in the company's financial health [1] Financial Performance - The company achieved a revenue of 1.019 billion yuan for the first three quarters, representing a year-on-year decrease of 2% [1] - The net profit attributable to shareholders was 220 million yuan, reflecting a year-on-year increase of 1.45% [1] - The non-recurring net profit was 173 million yuan, which is a year-on-year growth of 3.10% [1] - Basic earnings per share stood at 1.25 yuan [1]

Core Insights - The company reported a revenue of 1.019 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 2% [1] - The net profit attributable to shareholders reached 220 million yuan, showing a year-on-year increase of 1.45% [1] - The net profit excluding non-recurring items was 173 million yuan, reflecting a year-on-year growth of 3.10% [1] - The basic earnings per share stood at 1.25 yuan [1]

Financial Performance - The company's revenue for the third quarter was ¥364,685,045.87, a decrease of 1.55% compared to the same period last year[4]. - Total profit for the quarter reached ¥92,352,352.05, representing an increase of 28.42% year-over-year[4]. - Net profit attributable to shareholders was ¥83,590,556.58, up 18.52% from the previous year[4]. - The net profit after deducting non-recurring gains and losses was ¥69,186,088.86, reflecting a growth of 27.85% year-over-year[4]. - Total operating revenue for the first three quarters of 2025 was CNY 1,019,133,615.33, a decrease of 2.8% compared to CNY 1,039,937,156.56 in the same period of 2024[21]. - Net profit for the first three quarters of 2025 was CNY 220,162,482.66, slightly up from CNY 217,023,597.92 in 2024, representing a growth of 1.0%[23]. - The company reported a basic earnings per share of CNY 1.25 for the first three quarters of 2025, compared to CNY 1.24 in 2024[23]. Assets and Liabilities - The company's total assets increased by 4.67% to ¥3,558,922,033.10 compared to the end of the previous year[5]. - Current assets reached RMB 2,075,169,166.49, compared to RMB 1,928,705,677.43 at the end of 2024, indicating an increase of about 7.63%[17]. - Total liabilities stood at RMB 1,186,539,861.36, compared to RMB 1,189,252,367.98 at the end of 2024, showing a slight decrease of about 0.23%[18]. - The total liabilities decreased slightly to CNY 692,940,971.40 from CNY 702,205,924.57 year-over-year[22]. - The total equity attributable to shareholders increased to CNY 2,865,981,061.70, up from CNY 2,697,921,576.03, reflecting a growth of 6.2%[22]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥218,818,190.70, showing a significant increase of 49.21%[10]. - Operating cash flow for the first three quarters of 2025 increased to CNY 218,818,190.70, compared to CNY 146,646,770.03 in the same period of 2024, marking a significant increase of 49.2%[26]. - The company recorded a total cash inflow from operating activities of CNY 1,159,913,582.80, compared to CNY 1,027,032,791.52 in the previous year[26]. - The net cash flow from investing activities was -$586.19 million, compared to -$156.23 million in the previous period, indicating a significant increase in cash outflow[27]. - The net cash flow from financing activities was -$37.61 million, an improvement from -$175.47 million in the previous period[27]. - The company experienced a net decrease in cash and cash equivalents of -$405.18 million, compared to -$185.30 million in the previous period[27]. Research and Development - Research and development expenses totaled ¥62,188,527.85, a decrease of 25.99% compared to the same period last year[5]. - Research and development expenses for the first three quarters of 2025 were CNY 183,301,396.13, a slight decrease from CNY 188,129,351.01 in 2024[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,482[13]. - The top shareholder, Wang Ying, holds 34.89% of the shares, totaling 61,593,000 shares[13]. - The company has not reported any significant changes in the participation of major shareholders in margin financing or securities lending activities[15]. Other Information - The company recognized non-recurring gains totaling ¥14,404,467.72 for the quarter[8]. - The company will not apply new accounting standards starting from 2025[28].

证券代码：688513 证券简称：苑东生物 公告编号：2025-076 成都苑东生物制药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都苑东生物制药股份有限公司（以下简称"公司"）即将于 2025 年 10 月 28 日披露公司 2025 年第三季度报告，为加强与投资者的深入交流，使投资者更加 全面、深入地了解公司 2025 年第三季度的经营成果、财务指标等情况，公司计 划于 2025 年 10 月 31 日（星期五）上午 11:00-12:00 举行 2025 年第三季度业绩 说明会，就投资者关心的问题进行交流。 1 会议召开时间：2025 年 10 月 31 日（星期五）上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星 ...

华泰柏瑞价值增长混合A（460005）成立日期2008年7月16日，最新规模6.72亿。今年以来收益 40.63%，同类排名1503/8159；近一年收益42.89%，同类排名1127/8030；成立以来收益722.68%。 华泰柏瑞价值增长混合A（460005）基金经理为方纬。 截至发稿，方纬累计任职时间11年66天，现任基金资产总规模21.27亿元，任职期间最佳基金回报 260.51%， 任职期间最差基金回报-17.22%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 10月23日，苑东生物跌5.05%，截至发稿，报50.42元/股，成交4838.56万元，换手率0.53%，总市值 89.01亿元。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售78.75%，原料药销售9.22%，技术服务及转让 ...

Core Insights - The article highlights the journey of Yuandong Biopharmaceuticals and its chairman Wang Ying, focusing on the company's resilience and strategic decisions in the pharmaceutical industry [1][2]. Company Overview - Yuandong Biopharmaceuticals has transitioned from a focus on high-end generic drugs to innovative drug development, achieving significant progress in its drug pipeline [2][5]. - The company has successfully industrialized over 70 high-end chemical drugs, including 9 domestic first-generic products and 61 that have passed consistency evaluations [4]. Strategic Decisions - The company initially chose to develop high-end generic drugs to avoid competition in the low-end market, which has proven effective over the years [3]. - Yuandong Biopharmaceuticals has maintained a stable growth trajectory despite industry pressures, with a reported net profit of 137 million yuan in the first half of 2025, showing year-on-year growth after excluding stock incentive costs [3]. Research and Development - Since 2012, the company has invested in R&D, with a focus on innovative drugs, which it views as essential for future growth [5][6]. - The company employs a strategy of "using generics to promote innovation," allowing cash flow from generics to support the development of innovative drugs [7]. Clinical Progress - As of the first half of 2025, the company has made substantial advancements in its innovative drug pipeline, with over 80 projects under research, of which 24.4% are innovative drug projects [7]. - Notable achievements include the completion of clinical trials for several drugs, indicating a shift from initial development to broader market readiness [7]. Future Aspirations - Wang Ying expresses a vision for significant growth in both profits and revenue over the next decade, reflecting the company's long-term strategic goals [8].

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd. has received the drug registration certificate for "Elaidomide Tablets" from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1 - The active ingredient of Elaidomide Tablets is Elaidomide, which is indicated for the treatment of active rheumatoid arthritis [1] - Elaidomide Tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024) [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) has received a drug registration certificate for Elamomide tablets, indicating a significant regulatory approval for the company’s product aimed at treating active rheumatoid arthritis [1] Group 1: Company Information - The drug Elamomide, developed by the company's wholly-owned subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration (NMPA) [1] - Elamomide tablets are classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2024 [1]